CanSino Biologics Inc - Asset Resilience Ratio
CanSino Biologics Inc (CJH) has an Asset Resilience Ratio of 19.62% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CJH current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how CanSino Biologics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see CanSino Biologics Inc (CJH) total assets.
Liquid Assets Composition Over Time
This chart breaks down CanSino Biologics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read CanSino Biologics Inc total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.41 Billion | 19.62% |
| Total Liquid Assets | €1.41 Billion | 19.62% |
Asset Resilience Insights
- Good Liquidity Position: CanSino Biologics Inc maintains a healthy 19.62% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
CanSino Biologics Inc Industry Peers by Asset Resilience Ratio
Compare CanSino Biologics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for CanSino Biologics Inc (2016–2025)
The table below shows the annual Asset Resilience Ratio data for CanSino Biologics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 19.62% | €1.41 Billion ≈ $1.65 Billion |
€7.18 Billion ≈ $8.39 Billion |
-0.97pp |
| 2024-12-31 | 20.60% | €1.64 Billion ≈ $1.92 Billion |
€7.96 Billion ≈ $9.30 Billion |
-1.65pp |
| 2023-12-31 | 22.25% | €2.07 Billion ≈ $2.42 Billion |
€9.32 Billion ≈ $10.89 Billion |
-0.01pp |
| 2022-12-31 | 22.25% | €2.55 Billion ≈ $2.98 Billion |
€11.47 Billion ≈ $13.41 Billion |
+2.66pp |
| 2021-12-31 | 19.59% | €2.33 Billion ≈ $2.72 Billion |
€11.87 Billion ≈ $13.88 Billion |
+9.71pp |
| 2020-12-31 | 9.88% | €666.64 Million ≈ $779.37 Million |
€6.75 Billion ≈ $7.89 Billion |
-21.07pp |
| 2019-12-31 | 30.95% | €552.34 Million ≈ $645.75 Million |
€1.78 Billion ≈ $2.09 Billion |
+13.36pp |
| 2018-12-31 | 17.59% | €140.00 Million ≈ $163.67 Million |
€795.88 Million ≈ $930.46 Million |
-28.88pp |
| 2017-12-31 | 46.47% | €402.64 Million ≈ $470.72 Million |
€866.36 Million ≈ $1.01 Billion |
+17.66pp |
| 2016-12-31 | 28.82% | €94.00 Million ≈ $109.90 Million |
€326.17 Million ≈ $381.33 Million |
-- |
About CanSino Biologics Inc
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical … Read more